Evotec SE (EVO) Stock Analysis & Investment Frameworks
Evotec SE (EVO) stock analysis on Invetso. Review Evotec SE’s key financial metrics, company overview and 10 institutional-grade investment frameworks including SWOT Analysis, Economic Moat, Porter’s Five Forces and the Invetso Quality Score.
Evotec SE Company Overview
- Exchange: NASDAQ Global Select
- Sector: Healthcare
- Industry: Drug Manufacturers - Specialty & Generic
- Country: DE
Evotec SE Key Financial Metrics
- Market Cap: $546.98M
- Revenue: $848.11M
- ROE: -26.46%
- ROIC: -9.58%
- Dividend Yield: N/A
About Evotec SE
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Evotec SE Investment Frameworks
Invetso analyzes Evotec SE (EVO) across the following frameworks:
- Evotec SE 10Y Growth Potential
- Evotec SE Scenario Analysis
- Evotec SE Risks & Opportunities
- Evotec SE Economic Moat
- Evotec SE Business Model
- Evotec SE Management
- Evotec SE SWOT Analysis
- Evotec SE Porter's 5 Forces
- Evotec SE PESTLE Analysis
- Evotec SE ESG Analysis